Top Tweets for #ShanuModi
Just presented by #ShanuModi at #AACR25: Runimotamab (HER2xCD3 T-cell engager bispecific Ab) showed manageable safety when combined with trastuzumab and encouraging activity in heavily pretreated (median prior lines = 7) HER2+ breast cancer. @AACR
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @MammaMiaMagazin @AmericanCancer 8/17 #TumorBoardTuesday #BCSM
👩🏽🏫Mini tweetorial 5👩🏻🏫
✨DESTINY-Breast 04✨
📌T-DXd in HER2-low (+1, +2, neg FISH) MBC
📍Ph III comparing T-Dxd vs 👨🏾⚕️ choice chemo
💉1-2 lines of prior chemo
📈Vast improvement in PFS and OS in HER2-low pop
📚#ShanuModi https://t.co/wLKDWeg3kl
Phenomenal data in 2022, but 1 study that has resulted in a paradigm shift in how we treat/label #breastcancer
#DB04 by #ShanuModi from @MSKCancerCenter
Full Intv:
- https://t.co/UxeB1tqZWD
- Also on “Oncology Brothers” podcast
#OncJrnlClub #MedTwitter #OncEd @ASCO #bcsm
Breakthroughs of the Year from @TheAtlantic
https://t.co/BtmvTyDBlX
In the cancer arena, dramatic responses to #Immunotherapy in MSI+ cancers (@ldiaz1971 @AndreaCercek), Enhertu (#ShanuModi), & of course KRAS inhibitors (@kevansf & many others)
Informative talk on the present & future of ADCs by Dr. #ShanuModi @MSKCancerCenter
-Exciting era of ADCs with improved efficacy & broader clinical applicability
-Promising new ADCs constructs with unique targets & payloads
-Need biomarkers of response & well designed sequencing
What has changed in the last 20 years of HER2-targeting, and what’s on the horizon? Wonderful discussions with amazing experts & friends @JavierCortesMD @ErikaHamilton9 #ShanuModi during today’s symposium. Thanks @Medscape for having us!
Clear talk of the anti-HER2 future directions by #ShanuModi at #ESMO22
✅T-DXd represents the 1st approved ADC for #HER2Low breast cancer but new ADCs (single-agent &combo) are under investigation
✅Novel predictive markers are needed to personalize treatments
@OncoAlert
@myESMO
Join us in Hall 7, Honfleur Auditorium, to talk about the present and future of #HER2low breast cancer! @prat_aleix #ShanuModi #ESMO22
2h to go! 👇
Join us on Sept 9 at #ESMO22 Paris 🇫🇷 (or virtually) for a deep dive into the rapidly evolving landscape of #HER2low breast cancer!
@prat_aleix #ShanuModi #bcsm
It's not everyday you see a waterfall plot like this. No wonder #ShanuModi got a standing ovation @ #ASCO22!
The disease-control rate = 97.3% (95% CI, 93.8 - 99.1) & clinical-benefit rate = 76.1% (95% CI, 69.3 to 82.1) in pts w/ T-DM1 pretreated HER2+ metastatic breast cancer
#ASCO22'nin en dikkat çekici çalışması meme kanseri alanında geldi.
Kongre ile eşzamanlı NEJM dergisinde yayımlanan DESTINY-Breast04 adlı bu klinik çalışmayı sunduktan sonra Dr #ShanuModi, ayakta alkışlandı.
https://t.co/8hQcCiW9T6
@MSKCancerCenter #ASCO2022 super stars #ShanuModi & @AliSchram in my @ASCOPost updates. ADC trastuzumab deruxtecan is a game changer in patient care for #BreastCancer & zenocutuzumab is a much needed treatment option for #PancreaticCancer
#ASCO22
#DESTINYbreast04 opens a new era for metastatic #breastcancer classification and treatment👏
#HER2negative will never be the same again 🔬
@OncoAlert #HER2low #TrastuzumabDeruxtecan #bcsm #ShanuModi #DavidCameron @teamoncology @prat_aleix @hoperugo
https://t.co/Tr27tYFoHz
Finally it’s time for the #DESTINYbreast04 trial at #ASCO22 plenary session: so excited to be in the 2nd row of this big room to see such unprecedented results in the #BreastCancer field...this will remain one of the most important moment in the history of this disease
@OncoAlert
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.4M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.9M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.5M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.8M followers
KATY PERRY
@katyperry
87.3M followers
Taylor Swift
@taylorswift13
81.1M followers
Lady Gaga
@ladygaga
72.7M followers
Kim Kardashian
@kimkardashian
69.6M followers
Virat Kohli
@imvkohli
69.3M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.7M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62M followers
CNN
@cnn
61.9M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.4M followers